Business
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. Efzofitimod treatment reduces pro-inflammatory serum biomarkers in pulmonary sarcoidosis patients. Global pivotal Phase 3 EFZO-FIT™ study on track to initiate in the third quarter of 2022. SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that clinical data for efzofitimod (ATYR1923), its lead therapeutic candidate, will be presented in two posters today from 11:15AM – 1:15PM PT at the American Thoracic Society (ATS) 2022 International Conference in San Francisco, CA. “These posters present the clinical proof-of-concept data from the recently completed Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis. Efzofitimod was safe and well tolerated and demonstrated dose-dependent improvements in key physiologic and quality of life measures in the context of a steroid taper, which according to medical experts, is the first study of any therapy to do so in pulmonary sarcoidosis patients,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr. “Based on these findings, we are advancing efzofitimod to a pivotal Phase 3 study, which we expect to initiate in the third quarter of this year. EFZO-FIT™, a global, multi-center study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis, will be the first study in this patient population to evaluate steroid reduction as the primary endpoint and presents an opportunity to deliver a transformative therapy with clinically meaningful outcomes to these patients.” Details of the poster presentations appear below. The corresponding abstracts are available for review online on the conference website. The posters will be available on the aTyr website once presented. Title: Safety and Efficacy ATYR1923, a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial Abstract Number: 3932Poster Number: P559Poster Session: Inflammatory Modulation in Sarcoidosis, Lung Transplant, and Other DiseasesDate and Time: Tues...